Fiscal Year 2011 (FY11) Neurofibromatosis Research Program (NFRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Clinical Consortium Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-11-NFRP-CCA	Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).	 Support a consortium that will conceive, develop, and conduct collaborative clinical evaluations focused on NF1 and NF2 therapeutic interventions. Open to any group of institutions with a demonstrated history of collaborative NF research All applications must include letters of intent for conducting a minimum of four clinical trials; at least one NF1- and one NF2-focused study must be initiated within the first year of the award. 	 The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is \$9,000,000 in total costs. Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. Note that only \$5M total funding (direct and indirect costs) allocated for this award will be from the FY11 NFRP budget; the balance is contingent upon receipt of sufficient congressional appropriations to the NFRP in FY12 and FY13 	Pre-application (Pre-Proposal): June 22, 2011 5:00 p.m. Eastern time (ET) Invitation to Submit an Application: by July 13, 2011 Application: September 15, 2011 11:59 p.m. ET
Clinical Trial Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-11-NFRP-CTA	Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).	 Fund Phase 0, I, or II clinical trials relevant to NF and/or Schwannomatosis. Combinations of phases are permitted. Preclinical data required. Phase I or pilot clinical trial data required for Phase II clinical trial applications. 	 The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is \$900,000 in direct costs. Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	Pre-application (Pre-Proposal): June 22, 2011 5:00 p.m. Eastern time (ET) Invitation to Submit an Application: by July 13, 2011 Application: September 15, 2011 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Exploration – Hypothesis Development Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-11-NFRP-EHDA	All levels of experience.	 Fund the initial exploration of innovative, untested research and pursue serendipitous observations. Preliminary data is encouraged but not required. Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. 	 The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is \$100,000 in direct costs. Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 18, 2011 5:00 p.m. Eastern time (ET) Application: August 1, 2011 11:59 p.m. ET
Investigator-Initiated Research Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-11-NFRP-IIRA	Principal Investigator (PI): Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Optional Qualified Collaborator: Must be at or above the level of Assistant Professor (or equivalent).	 Fund basic and clinically oriented research relevant to NF and/or Schwannomatosis. Preliminary data required. Optional Qualified Collaborator: Collaborations that meet the criteria outlined in the Program Announcement/ Funding Opportunity will be qualified for a higher level of funding. Clinical trials not allowed. 	 The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is \$525,000 in direct costs (\$675,000 in direct costs if requesting an Optional Qualified Collaborator). Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 18, 2011 5:00 p.m. Eastern time (ET) Application: August 1, 2011 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Investigator-Initiated Focused Research Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-11-NFRP-IIFRA	PI: Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Optional Qualified Collaborator: Must be at or above the level of Assistant Professor (or equivalent).	 Fund basic and clinically oriented research relevant to NF and/or Schwannomatosis. Applications <i>must address</i> one or more of the following research focus areas: Pain, wound repair, nerve regeneration, stress and inflammation, and/or cognitive dysfunction. <i>Preliminary data required</i>. Optional Qualified Collaborator: Collaborations that meet the criteria outlined in the Program Announcement/ Funding Opportunity will be qualified for a higher level of funding. Clinical trials not allowed. 	 The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is \$525,000 in direct costs (\$675,000 in direct costs if requesting an Optional Qualified Collaborator). Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 18, 2011 5:00 p.m. Eastern time (ET) Application: August 1, 2011 11:59 p.m. ET
New Investigator Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-11-NFRP-NIA	Must be either an independent investigator <i>at or below</i> the level of Assistant Professor (or equivalent) or an established independent investigator <i>at or above</i> the level of Assistant Professor seeking to transition into a career in NF research. To be eligible, applicants may not have received more than \$300,000 in direct costs for NF research as a PI of one or more federally funded, non-mentored peer reviewed grants.	 Fund investigators in the early stages of their careers or established investigators seeking to transition into a career in NF research. Experience in NF research is allowed, but not required. Preliminary data required. Clinical trials not allowed. 	 The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is \$400,000 in direct costs. Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 18, 2011 5:00 p.m. Eastern time (ET) Application: August 1, 2011 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Postdoctoral Traineeship Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-11-NFRP-PTA	Postdoctoral Ph.D. PIs: Must have successfully defended a doctoral thesis by September 1, 2011; and Must not have been in the setting of the proposed research for more than 3 years; and Must have 5 years or less of postdoctoral research experience. Postdoctoral M.D. and D.O. PIs: Must have an M.D. or D.O. degree; and Must be able to devote at least 40% effort; and By August 1, 2011, must be: Enrolled in an accredited intern training program; or Enrolled in an accredited residency or fellowship training program with at least 2 years of training remaining; or Within 3 years of last formal training.	 Enable recent medical or other doctoral degree graduates to obtain the necessary experience to pursue an independent career in NF research. Funds can cover salary, travel, and tuition, but <i>not</i> research. 	 The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is \$100,000 in direct costs. Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 18, 2011 5:00 p.m. Eastern time (ET) Confidential Letters of Recommendation: August 1, 2011 5:00 p.m. ET Application: August 1, 2011 11:59 p.m. ET